Population-level Outcomes of Early Thyroid Cancers: A Need to Revisit Current Practice.
Journal
Rambam Maimonides medical journal
ISSN: 2076-9172
Titre abrégé: Rambam Maimonides Med J
Pays: Israel
ID NLM: 101538065
Informations de publication
Date de publication:
26 Apr 2022
26 Apr 2022
Historique:
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
29
4
2022
Statut:
epublish
Résumé
Early thyroid cancers have excellent long-term outcomes, yet the word "cancer" draws unnecessary apprehension. This study aimed to define when the recommendations for observation and surveillance may be extended to early thyroid cancers at the population level. Non-metastasized thyroid cancers ≤40 mm diameter were identified from the 1975-2016 Surveillance, Epidemiology and End Results (SEER) database. Causes of death were compared across demographic data. Disease-specific outcomes were compared to the age-adjusted healthy United States (US) population. Survival estimates were computed using Kaplan-Meier and compared using the Cox proportional hazard model. Dynamic benchmarks impacting disease-specific overall survival were determined by decision tree modeling and tested by the Cox model. Of the 28,728 thyroid cancers included in this study, 98.4% underwent some form of thyroid-specific treatment and were followed for a maximum of 10.9 years. This group had a 4.3% mortality rate at the end of follow-up (10.9 years maximum), with 13 times more deaths attributed to competing risks rather than thyroid cancer (stage T1a versus stage T1b, P=1.000; T1 versus T2, P<0.001). Among the untreated T1a or T1b tumors, the risk of disease-specific death was 21 times lower than death due to other causes. There was no significant difference between T1a and T1b tumors nor across sex. The age-adjusted risk of death for the healthy US population was higher than for the population with thyroid cancer. Dynamic categorization demonstrated worsening outcomes up to 73 years, uninfluenced by sex or tumor size. For patients over 73 years of age, only tumors >26 mm impacted outcomes. Based on the current data, T1a and T1b nodules have similar survival outcomes and are not significantly impacted even when left untreated. Multi-institutional prospective studies are needed to confirm these findings so that current observation and surveillance recommendations can be extended to certain T1 thyroid nodules.
Sections du résumé
BACKGROUND
BACKGROUND
Early thyroid cancers have excellent long-term outcomes, yet the word "cancer" draws unnecessary apprehension. This study aimed to define when the recommendations for observation and surveillance may be extended to early thyroid cancers at the population level.
METHODS
METHODS
Non-metastasized thyroid cancers ≤40 mm diameter were identified from the 1975-2016 Surveillance, Epidemiology and End Results (SEER) database. Causes of death were compared across demographic data. Disease-specific outcomes were compared to the age-adjusted healthy United States (US) population. Survival estimates were computed using Kaplan-Meier and compared using the Cox proportional hazard model. Dynamic benchmarks impacting disease-specific overall survival were determined by decision tree modeling and tested by the Cox model.
RESULTS
RESULTS
Of the 28,728 thyroid cancers included in this study, 98.4% underwent some form of thyroid-specific treatment and were followed for a maximum of 10.9 years. This group had a 4.3% mortality rate at the end of follow-up (10.9 years maximum), with 13 times more deaths attributed to competing risks rather than thyroid cancer (stage T1a versus stage T1b, P=1.000; T1 versus T2, P<0.001). Among the untreated T1a or T1b tumors, the risk of disease-specific death was 21 times lower than death due to other causes. There was no significant difference between T1a and T1b tumors nor across sex. The age-adjusted risk of death for the healthy US population was higher than for the population with thyroid cancer. Dynamic categorization demonstrated worsening outcomes up to 73 years, uninfluenced by sex or tumor size. For patients over 73 years of age, only tumors >26 mm impacted outcomes.
CONCLUSION
CONCLUSIONS
Based on the current data, T1a and T1b nodules have similar survival outcomes and are not significantly impacted even when left untreated. Multi-institutional prospective studies are needed to confirm these findings so that current observation and surveillance recommendations can be extended to certain T1 thyroid nodules.
Identifiants
pubmed: 35482460
pii: RMMJ.10467
doi: 10.5041/RMMJ.10467
pmc: PMC9049149
doi:
Types de publication
Journal Article
Langues
eng
Références
Endocr J. 2012;59(2):119-25
pubmed: 22068114
JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):317-22
pubmed: 24557566
J Clin Endocrinol Metab. 2014 Aug;99(8):2834-43
pubmed: 24828487
Am J Otolaryngol. 2005 Mar-Apr;26(2):87-90
pubmed: 15742259
World J Surg. 2008 May;32(5):747-53
pubmed: 18264828
N Engl J Med. 2016 Sep 15;375(11):1054-67
pubmed: 27626519
Bull World Health Organ. 1976;54(1):1-10
pubmed: 1087583
Arch Otolaryngol Head Neck Surg. 2010 May;136(5):440-4
pubmed: 20479371
Future Oncol. 2010 Nov;6(11):1771-9
pubmed: 21142662
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Thyroid. 2003 Apr;13(4):381-7
pubmed: 12804106
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Cell. 2014 Oct 23;159(3):676-90
pubmed: 25417114
Health Aff (Millwood). 2013 Jun;32(6):1143-52
pubmed: 23676531
Cancer. 1985 Aug 1;56(3):531-8
pubmed: 2408737
Am Health Drug Benefits. 2015 Feb;8(1):30-40
pubmed: 25964831
Clin Lab Sci. 2002 Winter;15(1):37-43
pubmed: 12778955
N Engl J Med. 2019 Oct 3;381(14):1378-1386
pubmed: 31577882
World J Surg. 2010 Jun;34(6):1222-31
pubmed: 20066418
BMJ. 2016 Nov 30;355:i5745
pubmed: 27903497
Thyroid. 2016 Jan;26(1):150-5
pubmed: 26426735
Laryngoscope. 2009 Oct;119(10):1983-7
pubmed: 19655332
Thyroid. 2016 Mar;26(3):373-80
pubmed: 26914539
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int Arch Otorhinolaryngol. 2017 Jan;21(1):38-41
pubmed: 28050206
World J Surg. 2010 Jan;34(1):28-35
pubmed: 20020290
World J Surg. 2014 Sep;38(9):2297-303
pubmed: 24791670
Med Arch. 2018 Apr;72(2):108-111
pubmed: 29736098
BMC Cancer. 2017 Feb 16;17(1):142
pubmed: 28209140